Equities

Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.69
  • Today's Change0.015 / 2.22%
  • Shares traded310.61k
  • 1 Year change-66.99%
  • Beta0.2536
Data delayed at least 15 minutes, as of Sep 20 2024 18:23 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Immunoprecise Antibodies Ltd grew revenues 18.65% from 20.67m to 24.52m while net income improved from a loss of 26.56m to a smaller loss of 27.18m.
Gross margin48.21%
Net profit margin-114.58%
Operating margin-123.33%
Return on assets-40.63%
Return on equity-63.68%
Return on investment-46.68%
More ▼

Cash flow in CADView more

In 2024, cash reserves at Immunoprecise Antibodies Ltd fell by 4.82m. Cash Flow from Financing totalled 1.02m or 4.16% of revenues. In addition the company used 4.25m for operations while cash used for investing totalled 1.56m.
Cash flow per share-0.6189
Price/Cash flow per share--
Book value per share0.8876
Tangible book value per share0.0428
More ▼

Balance sheet in CADView more

Immunoprecise Antibodies Ltd has a Debt to Total Capital ratio of 32.89%, a higher figure than the previous year's 16.29%.
Current ratio0.9862
Quick ratio0.8189
Total debt/total equity0.49
Total debt/total capital0.3289
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.